LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

Начало・Списък с акции・Geron Corp

Geron Corp

Затворен

СекторЗдравеопазване

1.42 1.43

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.37

Максимум

1.42

Ключови измерители
By Trading Economics
Приходи	-10M -29M
Продажби	788K 48M
Марж на печалбата	-60.11
Служители	258
EBITDA	-14M -24M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+132.14% upside

Дивиденти
By Dow Jones
Следващи печалби	6.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-143M 986M
Предишно отваряне	-0.01
Предишно затваряне	1.42

Настроения в новините

By Acuity

38%

62%

133 / 349 Класиране в Healthcare

Geron Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.03.2026 г., 23:15 ч. UTC

Значими събития в новините

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30.03.2026 г., 22:36 ч. UTC

Значими събития в новините

Australian Government Rules Out Boots on the Ground in the Middle East

30.03.2026 г., 22:13 ч. UTC

Придобивния, сливания и поглъщания

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30.03.2026 г., 21:00 ч. UTC

Печалби

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30.03.2026 г., 20:15 ч. UTC

Значими събития в новините

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30.03.2026 г., 23:40 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.03.2026 г., 23:40 ч. UTC

Пазарно говорене

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30.03.2026 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30.03.2026 г., 23:12 ч. UTC

Пазарно говорене

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30.03.2026 г., 22:49 ч. UTC

Пазарно говорене

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30.03.2026 г., 22:44 ч. UTC

Пазарно говорене

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30.03.2026 г., 22:43 ч. UTC

Пазарно говорене

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30.03.2026 г., 22:42 ч. UTC

Пазарно говорене

South32 Should Go for Growth, Says New Bull -- Market Talk

30.03.2026 г., 22:18 ч. UTC

Пазарно говорене

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30.03.2026 г., 22:05 ч. UTC

Пазарно говорене

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30.03.2026 г., 21:58 ч. UTC

Придобивния, сливания и поглъщания

Sun Life Financial Agrees to Buy Bell Partners for $350M

30.03.2026 г., 21:39 ч. UTC

Придобивния, сливания и поглъщания

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30.03.2026 г., 21:38 ч. UTC

Придобивния, сливания и поглъщания

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30.03.2026 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30.03.2026 г., 21:25 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.03.2026 г., 21:25 ч. UTC

Пазарно говорене

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30.03.2026 г., 21:03 ч. UTC

Придобивния, сливания и поглъщания

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

30.03.2026 г., 20:09 ч. UTC

Печалби

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30.03.2026 г., 20:00 ч. UTC

Значими събития в новините

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Сравнение с други в отрасъла

Ценова промяна

Geron Corp Прогноза

Ценова цел

By TipRanks

132.14% нагоре

12-месечна прогноза

Среден 3.25 USD 132.14%

Висок 5 USD

Нисък 1 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Geron Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Geron Corp през последните 3 месеца.

Настроение

By Acuity

133 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.